trending Market Intelligence /marketintelligence/en/news-insights/trending/xUMlFergNAmTJEt1EOphrg2 content esgSubNav
In This List

Roche again delays $4.3B Spark Therapeutics takeover amid regulatory scrutiny

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


Roche again delays $4.3B Spark Therapeutics takeover amid regulatory scrutiny

Roche Holding AG again extended its $4.3 billion takeover offer for Spark Therapeutics Inc. to give additional time to U.S. and U.K. regulators to examine the deal.

In March, Roche launched a buyout offer to acquire all outstanding shares of the Philadelphia-based gene-therapy maker for $114.50 apiece. Roche has already extended the offer period several times from the initial April 3 deadline.

The Swiss drugmaker said the offer will now expire at 5 p.m. ET on Dec. 16, unless further extended.